Pharma Services, CRO and CDMO Platforms

Drug development platform company providing predictive simulation, data-driven modeling, and AI tools; Phoenix and Simcyp platforms used by 75+ top pharma companies and all major regulatory agencies.

Premier cell and gene therapy CDMO offering comprehensive manufacturing for cell therapies, plasmid DNA, and advanced therapeutic medicinal products; acquired by Charles River Labs for $875M in 2021.

Clinical research organization providing regulatory-grade real-world evidence through disease registries; operates major patient registries for psoriasis, IBD, atopic dermatitis, and other conditions.

Middle-market PE firm founded 2021, focused exclusively on healthcare services, pharma, medical devices, and healthcare tech; actively investing in CROs, CDMOs, and specialty pharmacy.

UK-based pharmaceutical company focused on rare disease and oncology, known for Sylvant (siltuximab) approved for idiopathic multicentric Castleman's disease; acquired J&J's Sylvant rights for $115M in 2019.

Clinical trial software provider specializing in Randomization and Trial Supply Management (RTSM) solutions; operates PULSE and Elosity platforms across 90+ countries.

Leading revenue cycle management company managing $55B+ in net patient revenue for 200+ hospitals and health systems; combines certified operators and AI for RCM optimization.

Specialist powder-handling and inhalation CDMO with facilities in Cranbury, New Jersey and Kilbeggan, Ireland, offering process development, clinical manufacturing, packaging, and logistics for complex formulations.

European CDMO with 75+ years of heritage offering end-to-end contract development and manufacturing of finished dosage forms across sterile and non-sterile formats. Operates seven GMP-compliant sites across Germany, Greece, Italy, and Spain with ~1,850 employees.

Leading European CDMO specializing in small-molecule APIs and intermediates, founded in 1957. Operates three manufacturing sites in Italy with 1,800+ employees and FDA-inspected facilities. Controlled by Bain Capital following 2023 acquisition.

Global Contract Research Organization providing Phase I-IV clinical development, clinical pharmacology, and market access solutions across 90+ countries with 30+ years of expertise.

Biopharmaceutical company specializing in rare genetic disorders and immunology. Acquired by Sanofi in 2011 for $20.1 billion, representing one of the largest biotech acquisitions.

Sterile injectable fill-finish CDMO based in Grand Rapids, Michigan, with 450,000+ sq. ft. of GMP production space across five facilities specializing in aseptic fill-finish for vials, syringes, and cartridges.

Full-service global healthcare communications and strategic consultancy agency delivering multichannel communications solutions and medical education to pharma and biotech clients.

Largest pharma company by market cap; spun off Kenvue consumer health business in May 2023 via IPO raising $3.8B, allowing focus on pharmaceutical and medical device segments.

Leading U.S. middle-market private equity firm with $15 billion AUM headquartered in Mount Kisco, New York, focusing on industrial, healthcare services, and business services investments.

Clinical development company founded 2022 providing late-stage drug development services, regulatory strategy, and co-development partnerships with risk-financing model.

NASDAQ-traded sterile injectable CDMO with 40+ years of expertise in fill-finish, formulation development, and premium hyaluronic acid production. Serves biopharmaceutical clients across multiple therapeutic modalities with facilities in Minnesota and Europe.

Specialty pharmaceutical company with portfolio spanning branded and generic drugs; announced $6.7B merger with Endo in March 2025 to create scaled diversified pharma company.

Specialized CDMO founded 1999 focused on topical, transdermal, and transepithelial drug product development and manufacturing. Operates GMP facilities in UK and USA with expertise in dermal, ophthalmic, nasal, and mucosal delivery routes.

Mid-sized European CDMO formed from acquisition of Synerlab Group and seven former Recipharm sites, offering development and manufacturing across multiple pharmaceutical formats including lyophilization and sterile multidose.

International law firm founded in 1873 with 33 offices globally, providing strategic counsel in M&A, private equity, and life sciences transactions. Represents approximately 90% of Fortune 100 companies.

Holding company producing fuel additives, lubricant additives, and specialty chemicals through subsidiaries Afton Chemical and Ethyl Corporation; serves automotive, aviation, and industrial markets.

Global healthcare company founded 1923 and headquartered in Denmark with 10,000+ employees specializing in diabetes, obesity, hemophilia, and chronic disease treatments; major pharmaceutical customer and manufacturing partner.

Primary care platform serving Medicare-eligible seniors with 239 medical centers and 900+ providers across 27 states. Founded 2012, acquired by CVS Health for $11B in 2023; operates value-based primary care model with integrated preventive and social services.

Healthcare software company operating all-payer clearinghouse processing $250B+ in annual claims value; provides practice management, eligibility verification, and revenue recovery solutions.

Clinical-stage biopharmaceutical company developing innovative therapies for wet age-related macular degeneration and other retinal diseases using VEGF-C/D targeting technology.

Global contract research organization providing integrated drug development, clinical trial management, and laboratory services across 100+ countries, now owned by Thermo Fisher Scientific.

Clinical research organization providing Phase I to IV clinical development services and biopharmaceutical solutions with ~24,000 professionals globally and access to 30,000+ clinical trial sites.

Am Law 100 firm founded in 1972 with 22+ offices nationwide, recognized as a national leader in healthcare law and life sciences. Provides comprehensive corporate, transactional, and regulatory services.

Leading 503B outsourced sterile compounding pharmacy service provider operating five state-of-the-art facilities across the US, serving hospitals nationwide with ready-to-administer injectable medications.

Italian ophthalmic pharmaceutical company founded 1935, developing and manufacturing specialty eye care treatments across 60+ countries with innovative products for cataracts, glaucoma, infections, and retinopathies.

Global biopharmaceutical company specializing in R&D-driven development of medicines, vaccines, and healthcare solutions across immunology, oncology, neurology, rare diseases, and vaccines.

Multinational medical device manufacturer producing surgical equipment, orthopedic implants, neurosurgical devices, and patient handling systems sold in 75+ countries to 150 million patients annually.

Healthcare services company operating 300+ ambulatory surgery centers and surgical hospitals across 30 states, providing cost-effective outpatient surgical care and ancillary physician services.

Global integrated drug discovery CRO with 700+ scientists across 50+ nationalities, providing contract research services from target validation through preclinical development for pharma and biotech companies.

European CDMO specializing in small and medium batch contract development and manufacturing with six GMP-compliant production sites in France and Spain. Expertise spans solid dosage, sterile and non-sterile liquids, and specialized formulations.

Leading multinational pharmaceutical company specializing in generic medicines, complex pharmaceuticals, and specialty therapies, reaching approximately 200 million patients daily across 60 countries.

Global contract pharmaceutical packaging organization founded 1989 with FDA-approved facilities in Netherlands and USA. Specializes in primary and secondary packaging for oral solids, sterile injectables, and auto-injectors serving 40+ markets.

Global biopharmaceutical company founded 1928, specializing in neurological and autoimmune therapies; completed $1.9B acquisition of Zogenix in March 2022 to strengthen rare disease position.

Investment banking and capital markets division providing M&A advisory, investment banking, and global markets services; advised on major transactions including $82.7B Netflix-Warner Bros deal.

Contract development and manufacturing organization specializing in formulation development, analytical services, and clinical supply manufacturing, now part of Capsugel following 2015-16 acquisition.